GINKGO BIOWORKS HOLDINGS

NYSE: DNA (Ginkgo Bioworks Holdings, Inc.)

Last update: 5 days ago, 6:35AM

9.61

-0.62 (-6.06%)

Previous Close 10.23
Volume 1,859,962
Price / Sales 6.16
Price / Book 1.68
52 Weeks Range
5.37 (-44%) — 18.22 (89%)
Profit Margin -198.84%
Operating Margin (TTM) -182.09%
Diluted EPS (TTM) -8.91
Quarterly Revenue Growth (YOY) 27.30%
Total Debt/Equity (MRQ) 67.12%
Current Ratio (MRQ) 4.88
Operating Cash Flow (TTM) -281.85 M
Levered Free Cash Flow (TTM) -185.65 M
Return on Assets (TTM) -16.99%
Return on Equity (TTM) -57.76%

AIStockmoo Score

0.9
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
No clear trend over the past year. Far below its 52-week high. info
No clear trend: the price is moving around its moving averages. It is close to them. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mostly positive. info
Holdings' Sentiment info NA
Institutions net +7.36% of shares in their latest 13F filings: 91 holders increased, 79 decreased (quarter to 30 Sep 2026). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Above its medium-term trend line. info
Price is high against its 52-week average. Down over 5 years. info
Short-term momentum falling. info
Price is near support. info
Final Score 0.91
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Ginkgo Bioworks Holdings, Inc. Mixed Bearish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
DNA - - - 1.68 0.9
ADCT - - - - -1.3
ANVS - - - 16.34 -0.5
ANRO - - - 4.13 0.0
RCUS - - - 6.21 -1.8
NUVB - - - 6.18 -1.1

Select this tab to load the latest available analysis.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 6.88%
% Held by Institutions 77.96%

Ownership

Name Date Shares Held
Erste Asset Management Gmbh 30 Jun 2026 2,536,939
Forbes J M & Co Llp 30 Sep 2026 977,371

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 77.35%

Positions Holders Shares
Increased 91 5,547,261
Decreased 79 2,036,547
New 26 1,009,869
Sold out 31 546,570

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

3 Positive 0 Negative 3 Neutral
Date Type Details
12 Nov 2026 Yahoo Finance Ginkgo Bioworks Holdings Inc (DNA) Q3 2026 Earnings Call Highlights: Cost Cuts, First Big ...
Ginkgo Bioworks Holdings Inc (DNA) narrowed its net loss 44% and landed Novo Nordisk as its first autonomous lab customer, even as revenue slipped 6% and cash burn stayed high.
07 Nov 2026 Yahoo Finance Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
Ginkgo's shift to physical data for AI labs is the thread tying its cost discipline to its hardware ambitions.
07 Nov 2026 Yahoo Finance Ginkgo Bioworks Q3 Earnings Call Highlights
Ginkgo Bioworks (NYSE:DNA) reported lower third-quarter revenue but narrowed its loss as restructuring-related expense cuts took hold, while executives highlighted new customers for its autonomous laboratory systems and cloud-based lab services. Revenue from continuing operations fell 6% year over…
06 Nov 2026 Yahoo Finance Ginkgo Bioworks Holdings, Inc. Q3 2026 Earnings Call Summary
Moby summary of Ginkgo Bioworks Holdings, Inc.'s Q3 2026 earnings call…
06 Nov 2026 Yahoo Finance Ginkgo Bioworks (DNA) Q3 2026 Earnings Call Transcript
Ginkgo cut its quarterly loss 44% as it pivots to autonomous labs.
05 Nov 2026 Yahoo Finance Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
BOSTON, November 05, 2026--Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial…
29 Oct 2026 Yahoo Finance Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day.
24 Oct 2026 Yahoo Finance What Ginkgo Bioworks Bears Saw Before The Fall
Ginkgo Bioworks has just agreed to open its Boston autonomous lab to National Science Foundation X-Labs teams, while also wiring Araceli’s high-speed imaging gear into its Nebula setup. For Ginkgo Bioworks shareholders, the loss over the past year was 26.4%, including dividends. If you had…
20 Oct 2026 Yahoo Finance Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.
14 Oct 2026 Yahoo Finance Ginkgo Bioworks (DNA) Stock Fair Value Edges Higher After Analysts Reassess AI Demand
The latest analyst update on Ginkgo Bioworks Holdings includes a higher fair value estimate of US$8 and at least one price target set at US$11, which points to a reassessment of what investors might be willing to pay for the stock. That shift is closely linked to recent commentary that combines…
14 Oct 2026 Yahoo Finance Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
08 Oct 2026 Yahoo Finance Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston. The Endeavor, the world's fastest high-content imaging system, brings cellular imaging with real-time analysis…
07 Oct 2026 Yahoo Finance Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $11.47, moving 7.57% from the previous trading session.
05 Oct 2026 Yahoo Finance This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
Eli Lilly is partnering with Ginkgo Bioworks on drug discovery.
29 Sep 2026 Yahoo Finance Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
BOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium…
25 Sep 2026 Yahoo Finance What Needs To Be True To Buy Twist Bioscience Stock Now?
A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth…
23 Sep 2026 Yahoo Finance Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day.
18 Sep 2026 Yahoo Finance Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Show more

Recent Signals candle patterns and EMA crosses

▼ Bearish EMA cross 2 sessions ago · 11 Nov
Short term · EMA 7/20
The 7-day EMA crossed below the 20-day: short-term momentum turned down.

Technical Setup Medium

Trend order
Slope
Entry
Volume
No clear trend: the price is moving around its moving averages. It is close to them.
Nearest support: 8.92 – 11.00 · strong level · tested often, may give way
Nearest resistance: 10.78 – 11.50 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria